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ABSTRACT
Introduction: Airway inflammation is the pathological hallmark of chronic inflammatory airway diseases, especially 
asthma and chronic obstructive pulmonary disease (COPD). Airway epithelium plays an indispensable role in these 
diseases by secreting inflammatory mediators and cytokines in response to foreign substances, such as lipopolysac-
charide (LPS). Previous studies have shown that diarylpentanoid analogues, especially 5-(3,4-dihydroxyphenyl)-3-hy-
droxy-1-(2-hydroxyphenyl)penta-2,4-dien-1-one (DHHPD) and 2-benzoyl-6-(3,4-dihydroxybenzylidene)cyclohex-
en-1-ol (BDHBC), significantly inhibited nitric oxide (NO) production; suggesting their anti-inflammatory property. 
However, the therapeutic potential of DHHPD and BDHBC in airway inflammation has not been explored. Thus, 
this study aims to investigate their effects on interleukin (IL)-6 and IL-8 gene expression in LPS-induced Calu-3 cells, 
a cellular model of human airway epithelium. Methods: MTT cytotoxicity assay was carried out to identify non-cy-
totoxic concentrations of DHHPD and BDHBC on Calu-3 cells. RT-PCR was done to determine IL-6 and IL-8 gene 
expression levels. Results: DHHPD and BDHBC were not cytotoxic on Calu-3 cells up to 200µM. Four non-cyto-
toxic concentrations were chosen – 6.25, 12.5, 25 and 50µM to determine the effect of both compounds on gene 
expression. All four concentrations of DHHPD and BDHBC significantly inhibited LPS-induced mRNA expression of 
IL-6 while all concentrations of BDHBC, except 6.25µM, significantly reduced IL-8 mRNA expression. Similar find-
ing was obtained for DHHPD, except that at 50µM, there was no inhibition of IL-8 mRNA expression. Conclusion: 
Diarylpentanoid analogues, DHHPD and BDHBC, are proven to be effective in suppressing LPS-induced IL-6 and 
IL-8 gene expression. However, further studies are required to confirm their inhibitory effects on the production of 
pro-inflammatory cytokines. 
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INTRODUCTION
The initiation of an inflammatory response within human 
airways is a self-protective mechanism towards harmful 
environmental stimuli. These include pathogens such 
as bacteria, viruses and airborne irritants, such as dust, 
chemicals and tobacco smoke. While the response is 
usually protective and beneficial in its nature, it may 
also lead to tissue injury (1). Lipopolysaccharide (LPS), 
which is present as a contaminant on airborne particles, 
is capable of inducing cytokine production and 
inflammatory responses within the respiratory system, 
resulting in lung damage (2). Airway inflammation is the 
predominant feature of various chronic airway diseases, 
especially asthma and COPD (3). As airway epithelium 
acts as both physical and chemical barrier against 
pathogenic microorganisms or foreign substances to 
which human airways are constantly exposed, it is 
a crucial player in the development of inflammatory 
airway diseases. They are able to recruit immune cells 
and secrete cytokines, chemokines and antimicrobial 
peptides in response to harmful pathogens in the air (4). 
Thus, airway epithelial dysfunction represents one of the 
important events during asthma and COPD (5).
Cytokines are the crucial factors responsible for the 
initiation and progression of chronic inflammation 
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underlying various respiratory diseases (4). IL-6 is a 
pro-inflammatory cytokine secreted by a vast array 
of immune cells, such as leukocytes, mast cells and 
dendritic cells, as well as endothelial cells and airway 
epithelium (6). On the other hand, IL-8 functions as a 
chemoattractant that mediates neutrophils accumulation 
in the airways (7). Although IL-4, IL-5 and IL-13 are 
commonly implicated in the pathogenesis of allergic 
asthma, evidence has shown that IL-6 is responsible 
for regulating CD4 T cells responses by stimulating IL-4 
secretion, Th2 differentiation or/and Th17 differentiation 
(8). Besides that, IL-6 is also required for IL-13 production 
and mucous hypersecretion by lung epithelial cells (9). 
Due to the important roles played by IL-6 and IL-8 as 
described above, it is not surprising that IL-6 and IL-8 
were reported to be negatively correlated with pulmonary 
function of asthmatic and COPD patients (10, 11). 
Current treatment options for asthma and COPD include 
three different classes of inhaled therapies, which are 
inhaled corticosteroids (ICS), long-acting beta-2 (β2) 
agonists (LABAs) and long-acting muscarinic antagonists 
(LAMAs) (12). However, inflammation which often fails 
to resolve and resistance to corticosteroid remain the 
major hindrances for a successful treatment (13). Thus, 
efforts to look for alternative anti-inflammatory therapies 
for the management of both severe asthma and COPD 
are still underway.
Curcumin, a major constituent of turmeric (Curcuma 
longa), is popular among Chinese and Indian 
communities as a healing agent for diseases. The 
potency of curcumin as an anti-inflammatory and anti-
cancer agent has been well-validated in various studies 
(14). However, the therapeutic benefits of curcumin 
were hindered by its low bioavailability, low water 
solubility and poor chemical stability (15). Due to these 
reasons, researchers have been prompted to overcome 
the problems by using different drug delivery systems 
and through structural modifications of curcumin (14). 
As a result, there have been numerous analogues of 
curcumin being synthesised, including cyclohexanone, 
cyclopentanone and diarylpentanoid derivatives, 
with most of them being mono-carbonyl analogues of 
curcumin (16-19).
Several diarylpentanoid derivatives of curcumin have 
been proven to be excellent anti-inflammatory agents 
through their inhibition on different inflammatory 
mediators, cytokines and enzymes, such as IL-6, IL-
10, tumour necrosis factor-alpha (TNF-α), monocyte 
chemoattractant protein-1 (MCP-1), nitric oxide (NO), 
lipo-oxygenase (LOX) and cyclooxygenase (COX) (17, 
20-23). Leong et al. (22) synthesised a series of 97 
diarylpentanoid analogues and subsequently screened 
the compounds for anti-inflammatory potential using 
RAW264.7 macrophages challenged with both 
interferon gamma (IFN-γ) and LPS. More than half 
of the diarylpentanoids significantly inhibited NO 
production with 5-(3,4-dihydroxyphenyl)-3-hydroxy-1-
(2-hydroxyphenyl)penta-2,4-dien-1-one (DHHPD) (Fig. 
1A) as one of the compounds with the highest inhibition 
(98.9 ± 1.6%), comparable to that of curcumin (99.3 
± 0.2%). The NO suppression activity was attributed 
to the catechol or 3,4-dihydroxyl moiety of DHHPD, 
which is a polyphenolic diarylpentenedione analogue 
(22). Furthermore, DHHPD was found to exhibit both 
central and peripheral anti-nociceptive activities in 
animal models of nociception, which might be partly 
due to attenuated production of inflammatory mediators 
(24). In another series of 24 diarylpentanoid analogues, 
2-benzoyl-6-(3,4-dihydroxybenzylidene)cyclohexen-1-
ol (BDHBC) (Fig. 1B) was found to be the most effective 
compound in suppressing NO production by RAW264.7 
macrophages induced with both IFN-γ and LPS with an 
IC
50
 value of 4.2 ± 0.2µM, which was much lower than 
that of curcumin (14.7 ± 0.2µM). Most importantly, 
BDHBC demonstrated higher water solubility and 
stability compared to curcumin. Similar to DHHPD, the 
3,4-dihydroxylphenyl ring was the crucial determinant 
of the bioactivity of BDHBC (23).
Figure 1: Chemical structure of (A) DHHPD and (B) BDHBC. 
(A) 5-(3,4-dihydroxyphenyl)-3-hydroxy-1-(2-hydroxyphenyl)
penta-2,4-dien-1-one (DHHPD) and (B) 2-benzoyl-6-(3,4-di-
hydroxybenzylidene)cyclohexen-1-ol (BDHBC).
Despite numerous findings proving prominent anti-
inflammatory nature of diarylpentanoids, especially 
DHHPD and BDHBC, there has not been any study on 
these two diarylpentanoid analogues which explores 
their therapeutic potential in airway inflammation. Thus, 
this study aims to determine anti-inflammatory activities 
of DHHPD and BDHBC, particularly by assessing their 
effects on the gene expression of IL-6 and IL-8, which 
are key inflammatory cytokines released during airway 
inflammation.
 
MATERIALS AND METHODS
Reagents
Lipopolysaccharide (O111:B4) was purchased from 
Sigma Aldrich (St. Louis, MO, USA). Dimethyl 
sulfoxide (DMSO) and 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) were obtained 
from Amresco (Solon, OH, USA). RNeasy Plus Mini Kit 
12Mal J Med Health Sci 15(SP2): 10-17, July 2019
and OneStep RT-PCR Kit were obtained from Qiagen 
(Valencia, CA, USA).
Synthesis of DHHPD and BDHBC
Both diarylpentanoid analogues, DHHPD (Fig. 1A) and 
BDHBC (Fig. 1B), used in this study were synthesised 
at Institute of Bioscience, University Putra Malaysia. 
DHHPD and BDHBC were synthesised as previously 
described (22, 23).
Cell Culture
Calu-3, a human airway epithelial cell line derived from 
lung adenocarcinoma, was purchased from American 
Type Culture Collection (ATCC). Calu-3 was propagated 
in Eagle’s Minimum Essential Medium (EMEM) 
supplemented with 10% fetal bovine serum (FBS), 
1% sodium pyruvate, 100U/mL penicillin and 100µg/
mL streptomycin at 37˚C in humidified incubator with 
5% carbon dioxide. Cell culture medium was replaced 
every two days to ensure optimal growth condition 
for the cells. In this study, only Calu-3 cells between 
passage 15 to passage 25 were used. The selected range 
was within the passage range routinely used for this cell 
line, which was between 15 to 42 (25-27).
Cytotoxicity Assay
The cytotoxicity of both DHHPD and BDHBC on Calu-
3 cells was determined using 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) as described 
previously with slight modifications (20). Firstly, Calu-3 
cells were seeded onto a 96-well plate (2.0 x 104 cells/
well) in 100µL of complete EMEM medium. On the next 
day, the cells were treated with DHHPD or BDHBC, 
ranging from 10µM to 200µM, for 24 hours. After that, 
the medium with/without treatment was replaced with 
fresh EMEM medium and 20µL MTT solution (5mg/mL) 
was added into each well. After incubation in the dark 
for another 3 hours, the MTT solution was removed 
and the formazan crystals formed in each well were 
dissolved with 50µL DMSO. The amount of formazan 
crystals was quantified by determining the absorbance 
at 570nm with Tecan microplate reader (Mannedorf, 
Zurich, Switzerland).
Reverse Transcription-Polymerase Chain Reaction (RT-
PCR)
IL-6 and IL-8 gene expression levels of Calu-3 cells 
were determined as described previously with slight 
modifications (20). Calu-3 cells were seeded onto a 
6-well plate (8.0 x 105 cells/well) in 2mL of complete 
EMEM medium. Upon reaching 100% confluence, the 
cells were concurrently treated with DHHPD or BDHBC 
(6.25, 12.5, 25 and 50µM) and induced with LPS (10µg/
mL) for 24 hours. Dexamethasone (10µM) served as a 
positive drug control in this study. After 24 hours, total 
RNA was extracted from the cells using RNeasy Plus 
Mini Kit according to the manufacturer’s instructions. 
The purity and concentration of RNA were assessed 
using Implen NanoPhotometer (Schatzbogen, Munich, 
Germany) and 100ng total RNA were used as the initial 
template for reverse transcription. RT-PCR was done 
using Qiagen OneStep RT-PCR Kit under the following 
conditions: reverse transcription at 50˚C for 30 min, 
initial PCR activation at 95˚C for 15 min, 30 cycles of 
denaturation (94˚C for 1 min), annealing (60˚C, 45 sec 
for IL-6 or 55˚C, 45 sec for IL-8) and elongation (72˚C 
for 1 min), followed by final extension at 72˚C for 10 
min. The primers used in this study were purchased 
from Integrated DNA Technologies (Coralville, IA, 
USA) and the sequences were as follows: IL-6, forward 
5’-TGTAGCCGCCCCACACAGACAGCC-3’ and reverse 
5’-GGCAAGTCTCCTCATTGAATCCAGAGATTG-3’; IL-
8, forward 5’-ATGACTTCCAAGCTGGCCGTGGCT-3’ 
and reverse 5’-TCTCAGCCCTCTTCAAAAACTTCTC-3’; 
and GAPDH, forward 
5’-TGAAGGTCGGAGTCAACGGATTTGGT-3’ and 
reverse 5’-CATGTGGGCCATGAGGTCCACCAC-3’. 
Upon completion, separation of the RT-PCR products was 
carried out using a 2% agarose gel containing ethidium 
bromide (0.5µg/mL). After that, the gel was visualized 
with Fusion Fx imaging system (Vilber Lourmat) under 
UV light. The intensities of the immunoblots were 
determined using ImageJ software and normalized to 
that of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH).
Statistical Analysis
All values were presented as mean ± standard error of 
mean (SEM) of three separate experiments. GraphPad 
Prism 7.0 was used as the tool to perform statistical 
analyses. Data from different experimental groups 
were compared using one-way analysis of variance 
(ANOVA), followed by post hoc Dunnett’s test. Statistical 
significance was set at p < 0.05.
RESULTS
Effect of DHHPD and BDHBC on Calu-3 cell viability
The cytotoxicity of both diarylpentanoid analogues, 
DHHPD and BDHBC, on Calu-3 cells was determined 
using MTT cytotoxicity assay. As shown in Fig. 2, both 
DHHPD and BDHBC have no significant effect on 
Calu-3 cell viability for all tested concentrations. Four 
non-cytotoxic concentrations of DHHPD and BDHBC – 
6.25, 12.5, 25 and 50µM were chosen to be used in the 
subsequent assay.
Effect of DHHPD and BDHBC on IL-6 mRNA expression 
in LPS-induced Calu-3 cells
The effect of both diarylpentanoid analogues, DHHPD 
and BDHBC, on IL-6 and IL-8 gene expression was 
examined using RT-PCR. In comparison to Calu-3 cells 
without LPS induction, non-treated LPS-induced Calu-
3 cells showed more than two-fold increase of IL-6 
mRNA expression (Fig. 3A and 3B). However, Calu-3 
cells concurrently treated with DHHPD and induced 
with LPS showed significant reduction in IL-6 mRNA 
expression levels at all selected concentrations of 
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Figure 2: Effect of (A) DHHPD and (B) BDHBC on Calu-3 cell via-
bility. Both (A) DHHPD and (B) BDHBC were not cytotoxic to Calu-3 
cells at the range of concentrations used (10µM to 200µM). Data are 
expressed as mean ± standard error of mean (SEM) (n = 3). Cell viabil-
ities are presented as percentage of normal control (N). N: Calu-3 cells 
without any treatment; V: Vehicle control with 0.1% DMSO; DEX: 
Dexamethasone (10µM) as a positive drug control.
DHHPD. At 6.25µM, DHHPD attenuated LPS-induced 
IL-6 mRNA expression by almost 50%, whereas at 12.5, 
25 and 50µM approximately 70 – 80% inhibition was 
observed (Fig. 3A). Similar finding was observed in Calu-
3 cells concurrently treated with BDHBC and induced 
with LPS. BDHBC at 6.25µM significantly reduced IL-6 
mRNA expression level by more than 50% compared 
to LPS-stimulated but non-treated Calu-3 cells. On the 
other hand, the other three concentrations of BDHBC 
(12.5, 25 and 50µM) significantly reduced LPS-induced 
IL-6 mRNA expression by approximately 70% (Fig. 3B). 
Dexamethasone, a corticosteroid commonly prescribed 
for inflammatory airway diseases, also significantly 
suppressed IL-6 mRNA expression by about 75 – 85% 
(Fig. 3A and Fig. 3B). Thus, these indicated that both 
DHHPD and BDHBC were able to counteract the effect 
of LPS in airway inflammation by inhibiting IL-6 gene 
expression in Calu-3 airway epithelial cells.
Effect of DHHPD and BDHBC on IL-8 mRNA expression 
in LPS-induced Calu-3 cells
Similar to IL-6, mRNA expression levels of IL-8 were 
significantly increased in LPS-induced Calu-3 cells (Fig. 
Figure 3: Effect of (A) DHHPD and (B) BDHBC on IL-6 mRNA expres-
sion in LPS-induced Calu-3 cells. Both (A) DHHPD and (B) BDHBC 
significantly inhibited IL-6 mRNA expression in LPS-induced Calu-3 
cells at 6.25, 12.5, 25 and 50µM. Data are presented as mean ± stand-
ard error of mean (SEM) (n = 3). ***p < 0.001 and ****p < 0.0001 
represent significant difference compared to LPS-induced Calu-3 cells 
without any treatment (C: black bar). N: Calu-3 cells without LPS in-
duction and treatment; DEX: Dexamethasone (10µM) as a positive 
drug control.
4A and 4B). DHHPD was able to significantly decrease 
LPS-induced IL-8 mRNA expression at 12.5 and 25µM, 
both with approximately 40% inhibition. However, both 
the lowest and the highest concentration of DHHPD 
used, which were 6.25µM and 50µM respectively, were 
not effective in inhibiting the increase in IL-8 mRNA 
expression levels (Fig. 4A). On the other hand, BDHBC 
significantly suppressed IL-8 mRNA expression in LPS-
induced Calu-3 cells at 12.5, 25 and 50µM, with about 
28, 40 and 45% inhibition, respectively. The inhibitory 
effect on IL-8 mRNA expression increased when 
the concentration of BDHBC was higher. However, 
BDHBC at the lowest concentration (6.25µM) gave an 
insignificant inhibition of less than 10% (Fig. 4B). The 
inhibition on LPS-induced IL-8 mRNA expression due 
to dexamethasone was approximately 35% (Fig. 4A and 
4B).
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DISCUSSION
Cytokines are the key players that orchestrate diverse 
inflammatory responses. During chronic airway inflam-
mation, various inflammatory cytokines/chemokines 
are highly secreted by immune cells and bronchial ep-
ithelium, contributing to the disease severity of asthma 
and COPD. Thus, targeting pro-inflammatory cytokines, 
such as IL-6 and IL-8, may represent a potential thera-
peutic avenue for the treatment of these chronic inflam-
matory airway diseases (4).
IL-6 is one of the cytokines which is of clinical impor-
tance in chronic inflammatory airway diseases, especial-
ly asthma and COPD. Neveu et al. (28) suggested that 
IL-6 is an indicator of disease severity and progression 
of asthma, rather than just a pro-inflammatory marker, 
as the levels of IL-6 were increased in the sputum of 
patients with mild to moderate allergic asthma without 
active inflammation. In the same study, IL-6 levels were 
found to be positively correlated with that of IL-13, a 
cytokine responsible for stimulating mucous production 
by airway epithelial cells, subepithelial fibrosis and oth-
er pathological changes of asthma (28-30). Moreover, 
IL-6, together with IL-8, were shown to be determinants 
of the severity of COPD as increased levels of IL-6 and 
IL-8 were identified in COPD patients with marked ob-
struction of airways (31). Recently, Liu et al. (32) also re-
vealed that higher IL-8 levels were seen in patients with 
COPD exacerbations compared with asthma attacks, 
which was in line with the previous finding by Nocker 
et al. (33) that the increase in IL-8 was more pronounced 
in COPD patients in comparison to patients with asth-
ma. Based on the results of our current study, it has been 
shown that BDHBC is effective in inhibiting the expres-
sion of IL-6 and IL-8 at mRNA level in human airway 
epithelium, Calu-3 cells. With the aforementioned clin-
ical relevance of both cytokines in asthma and COPD, 
inhibitory effects of BDHBC on IL-6 and IL-8 gene ex-
pression justified the need for further study on BDHBC 
in airway inflammation.
On the other hand, DHHPD significantly inhibited IL-6 
mRNA expression at all concentrations. However, only 
12.5 and 25µM of DHHPD were able to significantly 
decrease LPS-induced IL-8 mRNA expression levels. It 
was surprising to note that DHHPD, at the highest con-
centration – 50µM, was not able to significantly suppress 
IL-8 mRNA expression. This unusual trend is similar to a 
biphasic dose response. This phenomenon, also known 
as hormesis, occurs when a drug or compound does 
not exhibit a classical linear or threshold dose-response 
relationship. In simple words, the drug elicits desirable 
effects at a low dose, but harmful effects at a high dose, 
even it is not toxic, resulting in a U-shape or an inverted 
U-shape dose-response curve (34).  At 50µM, DHHPD 
was proven to be non-cytotoxic on Calu-3 cells in MTT 
assay (Fig. 2A), thus, suggesting that the effect of DH-
HPD on IL-8 mRNA expression may follow a biphasic 
response.
Interestingly, curcumin has been suggested as one of 
the dietary phytochemicals that exhibit hormetic or bi-
phasic mode of action. It is well-known that curcumin 
has health-promoting benefits, which were later found 
to be partly attributed to the activation of adaptive cel-
lular stress response pathways. Mild stress activates dif-
ferent signalling pathways and triggers intrinsic changes 
within the cells, conferring resistance to more severe 
and detrimental stress responses.  However, the protec-
tion is lost when the dosage is beyond tolerable level 
(32). Since DHHPD was derived from the structure of 
curcumin, there is possibility that DHHPD may share 
similarity with curcumin, to a certain extent, in terms 
of its mechanism of action. But it should also be noted 
Figure 4: Effect of (A) DHHPD and (B) BDHBC on IL-8 mRNA expres-
sion in LPS-induced Calu-3 cells. (A) DHHPD significantly inhibited 
IL-8 mRNA expression in LPS-induced Calu-3 cells at 12.5 and 25µM. 
(B) BDHBC significantly inhibited IL-8 mRNA expression in LPS-in-
duced Calu-3 cells at 12.5, 25 and 50µM. Data are presented as mean 
± standard error of mean (SEM) (n = 3). *p < 0.05 and **p < 0.01 repre-
sent significant difference compared to LPS-induced Calu-3 cells with-
out any treatment (C: black bar). N: Calu-3 cells without LPS induction 
and treatment; DEX: Dexamethasone (10µM) as a positive drug control
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that the claim on the biphasic response of curcumin was 
made on the basis of its neuroprotective effects (35) and 
may not apply to other conditions. Nonetheless, further 
testing of the effect of DHHPD on IL-8 mRNA expres-
sion at higher concentrations may give a clearer picture 
on its pharmacological activity.
Previously, there have been quite a number of studies 
testing the effectiveness of curcumin against airway in-
flammation (36-40). In particular, an in vitro study by 
Lin et al. (36) elucidated that curcumin inhibited LPS-in-
duced inflammatory responses and mucous secretion in 
human bronchial epithelial (NCI-H292) cells through 
activation of nuclear factor erythroid 2-related factor 
2 (Nrf-2). The inhibitory effect of curcumin on LPS-in-
duced IL-6 and IL-8 expression has also been reported 
in a few in vitro studies using different cell lines. Jin et 
al. (41) revealed that curcumin was able to suppress 
IL-6 expression at mRNA levels in LPS-induced BV2 
microgial cells through inhibition of nuclear factor-κB 
(NF-κB) pathway. Jeong and Yun (42) also found that 
curcumin was capable of inhibiting LPS-induced neu-
trophils activation, including IL-6 and IL-8 protein lev-
els, by attenuating the activation of p38 mitogen activat-
ed protein kinases (p38), c-Jun amino-terminal kinases 
(JNK) and NF-κB. In another more recent study by Ma 
et al. (43), it has been shown that curcumin suppressed 
LPS-induced IL-6 mRNA expression in RAW264.7 mac-
rophages by decreasing microRNA-155 (miR-155) ex-
pression through phosphatidylinositol 3-kinase (PI3K)/
Protein kinase B (Akt) pathway. These findings may give 
some hints on how the curcumin analogues could also 
possibly work to reverse the effect of LPS. Curcumin 
is not a clinically approved drug for any inflammato-
ry airway diseases. Furthermore, although it has shown 
potential effect in reversing airway inflammation, its ef-
fect on LPS-induced inflammatory responses in Calu-3 
human airway epithelial cells, particularly on IL-6 and 
IL-8 expression, has not been previously investigated. 
Thus, a currently prescribed medication for airway in-
flammation – dexamethasone, was used as a positive 
drug control.
Notably, the inhibition on LPS-induced IL-6 mRNA lev-
els was stronger compared to that of IL-8 for both DH-
HPD and BDHBC. As indicated by the findings of Liu 
et al. (44), LPS-induced expression of pro-inflammatory 
cytokines, including IL-6 and IL-8, in human airway ep-
ithelial cells is mediated by nuclear factor-κB (NF-κB) 
and activator protein-1 (AP-1). Even so, either pathway 
may be more dominant in regulating LPS-induced IL-6 
or IL-8 gene expression. Sawa et al. (45) reported that 
inhibition of NF-κB resulted in greater reduction in IL-6 
levels compared to that of IL-8 in LPS-induced human 
lymphatic endothelial cells, indicating that NF-κB path-
way plays a more critical role in IL-6 expression. This 
may be the same in LPS-induced human airway epithe-
lial cells. Thus, the target signalling molecule of the dia-
rylpentanoid analogues, once identified, will give better 
explanation on why they exerted stronger inhibition on 
IL-6 mRNA expression. This is beyond the scope of our 
current study but should be the subject of further inves-
tigation.
This study serves to provide preliminary findings on the 
therapeutic potential of these two diarylpentanoid ana-
logues in airway inflammation. At this point, both DH-
HPD and BDHBC seem to target pro-inflammatory cyto-
kines, which are IL-6 and IL-8. There are other cytokines 
which are also implicated in airway inflammation, such 
as IL-1β and tumour necrosis factor (TNF)-α. The effect 
of the two diarylpentanoid analogues on the expression 
of these cytokines, at both mRNA and protein levels, 
should be assessed as well. This is because mRNA lev-
els do not always correlate well to protein levels due to 
variations in cell cycle and delay in the translation pro-
cess (46). As such, measurement of protein abundances 
of the cytokines could be done using Western blot or 
enzyme-linked immunosorbant assay (ELISA) to confirm 
their effect on cytokine production. Nevertheless, BDH-
BC and DHHPD deserve seats as candidate compounds 
worth to be further investigated to validate their thera-
peutic benefits in airway inflammation.
CONCLUSION
In conclusion, both diarylpentanoid analogues, DHHPD 
and BDHBC, are proven to be effective in inhibiting the 
gene expression of IL-6 and IL-8 in LPS-induced airway 
inflammation. Since this is a preliminary study to give 
insights on the therapeutic potential of diarylpentanoid 
analogues in airway inflammation, further investigations 
are needed to elucidate their mechanisms of action in 
regulating pro-inflammatory cytokines, such as IL-6 and 
IL-8, or other key cytokines - IL-1β and TNF-α, in order 
for them to be developed as potential therapeutic drug 
for asthma and COPD.
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